What is new in non-muscle-invasive bladder cancer in 2016?

Kamat, Ashish M.; Bağcıoğlu, Murat; Hurі, Emre

doi:10.5152/tud.2017.60376

Cited by 35 publications

(47 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with non-muscle invasive bladder tumor (NMIBT) have been documented to have good prognosis after surgical excision of tumor cells. 13 Till date, TURBT have been the gold standard procedure for patients with NMIBT. the effectiveness of immediate instillation of chemotherapeutic agents into the intra-vesical sac, 14,15 this protocol has also gained worldwide acceptance.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Single Dose Intravesical Mitomycin C Therapy as Prophylaxis to Prevent Recurrence and Progression of Superficial Nonmuscle Invasive Bladder Tumor.

Saulat¹,

Soomro

Azad

2019

TPMJ

View full text Add to dashboard Cite

Objectives: To determine the effectiveness of instillation of single dose of intravesical mitomycin C in patients with low grade non-muscle invasive bladder tumor (NMIBT). Study Design: Retrospective cross-sectional study. Setting: Tabba kidney institute Karachi. Period: 2016 to Jan-2018. Subject and Methods: A total of 76 patients with first time diagnosis of non-invasive bladder tumor were included. Data of patients of SNMIBT who underwent trans-uretheral resection of bladder tumor (TURBT) and received single dose instillation of mitomycin C (MMC, 40 mg) within 24 hours after resection from 2016 to Jan-2018 were included in this analysis. All these patients were followed for 6 months after TURBT, cystoscopy was performed at 3 and 6 monthly to check and record any recurrence or progression. Results: Out of 76 cases, 43 (56.57%) had one lesion, 27 (35.52%) had two lesion and 6 (7.89%) cases had three lesion. Single dose intravesical mitomycin C was effective in 81.57% (62/76) cases, recurrence occurred in 6 (7.89 %) cases and progression of disease in 8 (10.52%) cases. Conclusion: The results of present study confirmed the positive effect of instillation of single immediate dose of MMC in patients with low risk superficial bladder tumor. 81.57% patients will not require any further treatment if MMC-40 is given immediately following TURBT.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of Single Dose Intravesical Mitomycin C Therapy as Prophylaxis to Prevent Recurrence and Progression of Superficial Nonmuscle Invasive Bladder Tumor.

Saulat¹,

Soomro

Azad

2019

TPMJ

View full text Add to dashboard Cite

show abstract

“…The detection of a tumor will require full anaesthesia for its resection necessitating a rigid cystoscope for the introduction of a surgical instrument to perform a partial or complete resection of the tumor. At first presentation, approximately 75% of cases are classified as non-muscle-invasive bladder cancer [56], which is associated with a five-year survival rate of 88-98% [57]. These tumors are classified as stage Ta if they have retained the basement membrane or as stage T1 if they have invaded the submucosal region called the chorion.…”

Section: Invasive Techniquesmentioning

confidence: 99%

Microdevices for Non-Invasive Detection of Bladder Cancer

et al. 2017

View full text Add to dashboard Cite

Bladder cancer holds the record for the highest lifetime cost on a per-patient basis. This is due to high recurrence rates, which necessitate invasive and costly long-term evaluation methods such as cystoscopy and imaging. Microfluidics is emerging as an important approach to contribute to initial diagnosis and follow-up, by enabling the precise manipulation of biological samples. Specifically, microdevices have been used for the isolation of cells or genetic material from blood samples, sparking significant interest as a versatile platform for non-invasive bladder cancer detection with voided urine. In this review, we revisit the methods of bladder cancer detection and describe various types of markers currently used for evaluation. We detail cutting-edge technologies and evaluate their merits in the detection, screening, and diagnosis of bladder cancer. Advantages of microscale devices over standard methods of detection, as well as their limitations, are provided. We conclude with a discussion of criteria for guiding microdevice development that could deepen our understanding of prognoses at the level of individual patients and the underlying biology of bladder cancer development. Collectively, the development and widespread application of improved microfluidic devices for bladder cancer could drive treatment breakthroughs and establish widespread, tangible outcomes on patients' long-term survival.

show abstract

“…Bladder cancer (BC) is multifocal in almost half of the cases with primary tumour and in more than 50% of the patients with recurrent non-muscle invasive BC (NMIBC) 14 . Moreover, recurrent BC is common as the majority of the patients with non-muscle invasive BC (NMIBC) relapse within five years 15,16 . Approximately 75% of patients with BC present with NMIBC, and 5-25% of these will progress to muscle-invasive bladder cancer (MIBC) 16,17 .…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, recurrent BC is common as the majority of the patients with non-muscle invasive BC (NMIBC) relapse within five years 15,16 . Approximately 75% of patients with BC present with NMIBC, and 5-25% of these will progress to muscle-invasive bladder cancer (MIBC) 16,17 . Multifocality and the frequent recurrences of BC are hypothesized to originate from field cancerization of the bladder urothelium 18 .…”

Section: Introductionmentioning

confidence: 99%

Mutational analysis of field cancerization in bladder cancer

Strandgaard

Nordentoft

Lamy

et al. 2019

Preprint

View full text Add to dashboard Cite

31By applying whole exome sequencing and deep targeted sequencing on bladder 32 tumors, it was recently shown that tumors developed years apart in the same patients 33 share multiple mutations and hence are clonally related 1-3 . Furthermore, apparently 34 normal urothelium has been documented to contain mutations with low allele 35 frequencies (~3%) that are typically observed at high frequencies in tumors (clonal 36 mutations) 1-3 . Multiple studies have investigated genomic alterations in normal 37 appearing bladder tissue from cystectomy specimens, however using technologies 38 that do not allow detection of low-frequency mutations. The genomic alterations 39 observed in these studies include copy number alterations of chromosome 5, 9, 13, 40 16, and 17 as well as mutations or loss of RB1 and TP53 4-9 . These findings 41 corroborates the suggestions of the presence of field cancerization in the bladder. 42 Similar results have been reported in other tissue types, where studies have revealed 43 the presence of mutations in well-characterized cancer driver genes in apparently 44 healthy tissue and pre-cancer lesions 10-13 . 45 46 Bladder cancer (BC) is multifocal in almost half of the cases with primary tumour and 47 101 102 Analysis of field cancerization. Patients 1 and 2 presented with multifocal disease, 103 whereas patients 3 and 4 had unifocal disease. In patients 1 and 2, 39% (25/64) of the 104 mutations were N-Mutations, and 34% (22/64) were S-Mutations. Mutations called in 105 patients 3 and 4 were mainly T-Mutations, with only 5% (7/143) being N-Mutations and 106 13% (19/143) S-Mutations -indicating that uni-and multifocal patients may show 107 different levels of field cancerization. Mutations in known BC driver genes were 108 detected in both N-, S-and T-Mutation groups, most of them being among T-109 Mutations. However, in patient 1, two N-mutations were observed in bladder cancer 110 driver genes. Damaging mutations were present in all N-, S-and T-Mutation groups. 111 We detected the introduction of premature stop codons, mainly in the T-Mutation 112 group. However, for patient 1 premature stop codons were solely observed within the 113 N-and S-Mutations. Mutation allele frequencies (AFs) varied for the different 114 mutations detected but were generally low for N-Mutations and high for T-Mutations. 115 See Figure 1b and Table 1 for details. 116 117 131 132 Allele frequencies (median (min-max)) N-Mutations 0.042 (0.029-0.091) 0.067 (0.035-0.15) 0.070 (0.049-0.091) 0.059 (0.049-0.091) T-Mutations 0.23 (0.049-0.31) 0.13 (0.031-0.40) 0.17 (0.039-0.50) 0.16 (0.032-0.67) S-Mutations (Normal pool) 0.022 (0.0074-0.14) 0.033 (0.0064-0.063) 0.10 (0.014-0.13) 0.025 (0.0065-0.13) S-Mutations (Tumor pool) 0.20 (0.067-0.44) 0.077 (0.016-0.56) 0.13 (0.057-0.19) 0.15 (0.020-0.61)

show abstract

What is new in non-muscle-invasive bladder cancer in 2016?

Cited by 35 publications

References 36 publications

Effectiveness of Single Dose Intravesical Mitomycin C Therapy as Prophylaxis to Prevent Recurrence and Progression of Superficial Nonmuscle Invasive Bladder Tumor.

Effectiveness of Single Dose Intravesical Mitomycin C Therapy as Prophylaxis to Prevent Recurrence and Progression of Superficial Nonmuscle Invasive Bladder Tumor.

Microdevices for Non-Invasive Detection of Bladder Cancer

Mutational analysis of field cancerization in bladder cancer

Contact Info

Product

Resources

About